nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A5—Gefitinib—lung cancer	0.0527	0.0742	CbGbCtD
Salmeterol—CYP3A5—Teniposide—lung cancer	0.0511	0.0719	CbGbCtD
Salmeterol—CYP3A7—Paclitaxel—lung cancer	0.038	0.0535	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.038	0.0535	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.0375	0.0528	CbGbCtD
Salmeterol—CYP3A7—Irinotecan—lung cancer	0.0375	0.0528	CbGbCtD
Salmeterol—CYP3A5—Crizotinib—lung cancer	0.0323	0.0455	CbGbCtD
Salmeterol—CYP3A5—Erlotinib—lung cancer	0.0312	0.0438	CbGbCtD
Salmeterol—CYP2C8—Erlotinib—lung cancer	0.03	0.0422	CbGbCtD
Salmeterol—CYP3A5—Paclitaxel—lung cancer	0.0285	0.0401	CbGbCtD
Salmeterol—CYP3A5—Irinotecan—lung cancer	0.0281	0.0396	CbGbCtD
Salmeterol—CYP3A7—Docetaxel—lung cancer	0.0275	0.0387	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.0275	0.0387	CbGbCtD
Salmeterol—CYP2C8—Paclitaxel—lung cancer	0.0274	0.0386	CbGbCtD
Salmeterol—CYP3A5—Etoposide—lung cancer	0.0225	0.0317	CbGbCtD
Salmeterol—CYP3A4—Topotecan—lung cancer	0.0225	0.0316	CbGbCtD
Salmeterol—CYP2C8—Etoposide—lung cancer	0.0217	0.0305	CbGbCtD
Salmeterol—CYP3A5—Docetaxel—lung cancer	0.0206	0.029	CbGbCtD
Salmeterol—CYP3A4—Gefitinib—lung cancer	0.0205	0.0289	CbGbCtD
Salmeterol—CYP3A4—Teniposide—lung cancer	0.0199	0.028	CbGbCtD
Salmeterol—CYP3A4—Vinorelbine—lung cancer	0.0158	0.0223	CbGbCtD
Salmeterol—CYP3A4—Crizotinib—lung cancer	0.0126	0.0177	CbGbCtD
Salmeterol—CYP3A4—Erlotinib—lung cancer	0.0121	0.0171	CbGbCtD
Salmeterol—CYP3A4—Paclitaxel—lung cancer	0.0111	0.0157	CbGbCtD
Salmeterol—CYP3A4—Irinotecan—lung cancer	0.011	0.0154	CbGbCtD
Salmeterol—CYP3A4—Vinblastine—lung cancer	0.00975	0.0137	CbGbCtD
Salmeterol—CYP3A4—Etoposide—lung cancer	0.00879	0.0124	CbGbCtD
Salmeterol—CYP3A4—Docetaxel—lung cancer	0.00804	0.0113	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—lung cancer	0.00599	0.00844	CbGbCtD
Salmeterol—Abdominal discomfort—Methotrexate—lung cancer	0.000163	0.000745	CcSEcCtD
Salmeterol—Fatigue—Gemcitabine—lung cancer	0.000163	0.000745	CcSEcCtD
Salmeterol—Pain—Gemcitabine—lung cancer	0.000162	0.000738	CcSEcCtD
Salmeterol—Constipation—Gemcitabine—lung cancer	0.000162	0.000738	CcSEcCtD
Salmeterol—Nausea—Erlotinib—lung cancer	0.000162	0.000738	CcSEcCtD
Salmeterol—Dry mouth—Paclitaxel—lung cancer	0.000161	0.000738	CcSEcCtD
Salmeterol—Anaphylactic shock—Etoposide—lung cancer	0.000161	0.000737	CcSEcCtD
Salmeterol—Diarrhoea—Vinorelbine—lung cancer	0.000161	0.000735	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000161	0.000733	CcSEcCtD
Salmeterol—Infection—Etoposide—lung cancer	0.00016	0.000733	CcSEcCtD
Salmeterol—Feeling abnormal—Irinotecan—lung cancer	0.00016	0.000731	CcSEcCtD
Salmeterol—Back pain—Docetaxel—lung cancer	0.000159	0.000726	CcSEcCtD
Salmeterol—Gastrointestinal pain—Irinotecan—lung cancer	0.000159	0.000725	CcSEcCtD
Salmeterol—Anaphylactic shock—Paclitaxel—lung cancer	0.000158	0.000723	CcSEcCtD
Salmeterol—Oedema—Paclitaxel—lung cancer	0.000158	0.000723	CcSEcCtD
Salmeterol—Paraesthesia—Cisplatin—lung cancer	0.000158	0.000723	CcSEcCtD
Salmeterol—Muscle spasms—Docetaxel—lung cancer	0.000158	0.000722	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Methotrexate—lung cancer	0.000158	0.000722	CcSEcCtD
Salmeterol—Tachycardia—Etoposide—lung cancer	0.000158	0.00072	CcSEcCtD
Salmeterol—Infection—Paclitaxel—lung cancer	0.000157	0.000718	CcSEcCtD
Salmeterol—Dyspnoea—Cisplatin—lung cancer	0.000157	0.000718	CcSEcCtD
Salmeterol—Skin disorder—Etoposide—lung cancer	0.000157	0.000716	CcSEcCtD
Salmeterol—Feeling abnormal—Gemcitabine—lung cancer	0.000156	0.000712	CcSEcCtD
Salmeterol—Dizziness—Vinorelbine—lung cancer	0.000156	0.000711	CcSEcCtD
Salmeterol—Abdominal pain upper—Doxorubicin—lung cancer	0.000156	0.000711	CcSEcCtD
Salmeterol—Nervous system disorder—Paclitaxel—lung cancer	0.000155	0.000709	CcSEcCtD
Salmeterol—Tachycardia—Paclitaxel—lung cancer	0.000154	0.000706	CcSEcCtD
Salmeterol—Skin disorder—Paclitaxel—lung cancer	0.000154	0.000702	CcSEcCtD
Salmeterol—Abdominal pain—Irinotecan—lung cancer	0.000153	0.000701	CcSEcCtD
Salmeterol—Body temperature increased—Irinotecan—lung cancer	0.000153	0.000701	CcSEcCtD
Salmeterol—Pneumonia—Methotrexate—lung cancer	0.000152	0.000697	CcSEcCtD
Salmeterol—Nasopharyngitis—Doxorubicin—lung cancer	0.000152	0.000696	CcSEcCtD
Salmeterol—Infestation NOS—Methotrexate—lung cancer	0.000152	0.000693	CcSEcCtD
Salmeterol—Infestation—Methotrexate—lung cancer	0.000152	0.000693	CcSEcCtD
Salmeterol—Pain—Cisplatin—lung cancer	0.000151	0.000688	CcSEcCtD
Salmeterol—Vomiting—Vinorelbine—lung cancer	0.00015	0.000683	CcSEcCtD
Salmeterol—Body temperature increased—Gemcitabine—lung cancer	0.000149	0.000683	CcSEcCtD
Salmeterol—Rash—Vinorelbine—lung cancer	0.000148	0.000678	CcSEcCtD
Salmeterol—Dermatitis—Vinorelbine—lung cancer	0.000148	0.000677	CcSEcCtD
Salmeterol—Headache—Vinorelbine—lung cancer	0.000147	0.000673	CcSEcCtD
Salmeterol—Conjunctivitis—Methotrexate—lung cancer	0.000147	0.000673	CcSEcCtD
Salmeterol—Influenza—Doxorubicin—lung cancer	0.000147	0.000673	CcSEcCtD
Salmeterol—Asthma—Doxorubicin—lung cancer	0.000147	0.000673	CcSEcCtD
Salmeterol—Palpitations—Docetaxel—lung cancer	0.000145	0.000664	CcSEcCtD
Salmeterol—Feeling abnormal—Cisplatin—lung cancer	0.000145	0.000663	CcSEcCtD
Salmeterol—Paraesthesia—Etoposide—lung cancer	0.000145	0.000662	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000144	0.000659	CcSEcCtD
Salmeterol—Dyspnoea—Etoposide—lung cancer	0.000144	0.000657	CcSEcCtD
Salmeterol—Cough—Docetaxel—lung cancer	0.000143	0.000655	CcSEcCtD
Salmeterol—Insomnia—Paclitaxel—lung cancer	0.000143	0.000654	CcSEcCtD
Salmeterol—Epistaxis—Methotrexate—lung cancer	0.000143	0.000653	CcSEcCtD
Salmeterol—Hypersensitivity—Irinotecan—lung cancer	0.000143	0.000653	CcSEcCtD
Salmeterol—Paraesthesia—Paclitaxel—lung cancer	0.000142	0.000649	CcSEcCtD
Salmeterol—Hypertension—Docetaxel—lung cancer	0.000142	0.000648	CcSEcCtD
Salmeterol—Bronchitis—Doxorubicin—lung cancer	0.000142	0.000647	CcSEcCtD
Salmeterol—Dyspnoea—Paclitaxel—lung cancer	0.000141	0.000645	CcSEcCtD
Salmeterol—Chest pain—Docetaxel—lung cancer	0.00014	0.000639	CcSEcCtD
Salmeterol—Arthralgia—Docetaxel—lung cancer	0.00014	0.000639	CcSEcCtD
Salmeterol—Myalgia—Docetaxel—lung cancer	0.00014	0.000639	CcSEcCtD
Salmeterol—Nausea—Vinorelbine—lung cancer	0.00014	0.000639	CcSEcCtD
Salmeterol—Dyspepsia—Paclitaxel—lung cancer	0.000139	0.000636	CcSEcCtD
Salmeterol—Body temperature increased—Cisplatin—lung cancer	0.000139	0.000636	CcSEcCtD
Salmeterol—Asthenia—Irinotecan—lung cancer	0.000139	0.000636	CcSEcCtD
Salmeterol—Fatigue—Etoposide—lung cancer	0.000139	0.000636	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000139	0.000635	CcSEcCtD
Salmeterol—Pain—Etoposide—lung cancer	0.000138	0.000631	CcSEcCtD
Salmeterol—Constipation—Etoposide—lung cancer	0.000138	0.000631	CcSEcCtD
Salmeterol—Dry mouth—Docetaxel—lung cancer	0.000137	0.000625	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000137	0.000625	CcSEcCtD
Salmeterol—Fatigue—Paclitaxel—lung cancer	0.000136	0.000623	CcSEcCtD
Salmeterol—Asthenia—Gemcitabine—lung cancer	0.000136	0.00062	CcSEcCtD
Salmeterol—Pain—Paclitaxel—lung cancer	0.000135	0.000618	CcSEcCtD
Salmeterol—Constipation—Paclitaxel—lung cancer	0.000135	0.000618	CcSEcCtD
Salmeterol—Pharyngitis—Methotrexate—lung cancer	0.000135	0.000617	CcSEcCtD
Salmeterol—Anaphylactic shock—Docetaxel—lung cancer	0.000134	0.000613	CcSEcCtD
Salmeterol—Oedema—Docetaxel—lung cancer	0.000134	0.000613	CcSEcCtD
Salmeterol—Infection—Docetaxel—lung cancer	0.000133	0.000609	CcSEcCtD
Salmeterol—Feeling abnormal—Etoposide—lung cancer	0.000133	0.000608	CcSEcCtD
Salmeterol—Hyperglycaemia—Doxorubicin—lung cancer	0.000133	0.000607	CcSEcCtD
Salmeterol—Diarrhoea—Irinotecan—lung cancer	0.000133	0.000607	CcSEcCtD
Salmeterol—Pneumonia—Doxorubicin—lung cancer	0.000132	0.000603	CcSEcCtD
Salmeterol—Gastrointestinal pain—Etoposide—lung cancer	0.000132	0.000603	CcSEcCtD
Salmeterol—Nervous system disorder—Docetaxel—lung cancer	0.000132	0.000601	CcSEcCtD
Salmeterol—Infestation—Doxorubicin—lung cancer	0.000131	0.0006	CcSEcCtD
Salmeterol—Infestation NOS—Doxorubicin—lung cancer	0.000131	0.0006	CcSEcCtD
Salmeterol—Tachycardia—Docetaxel—lung cancer	0.000131	0.000598	CcSEcCtD
Salmeterol—Feeling abnormal—Paclitaxel—lung cancer	0.00013	0.000596	CcSEcCtD
Salmeterol—Skin disorder—Docetaxel—lung cancer	0.00013	0.000595	CcSEcCtD
Salmeterol—Hypersensitivity—Cisplatin—lung cancer	0.00013	0.000593	CcSEcCtD
Salmeterol—Gastrointestinal pain—Paclitaxel—lung cancer	0.000129	0.000591	CcSEcCtD
Salmeterol—Diarrhoea—Gemcitabine—lung cancer	0.000129	0.000591	CcSEcCtD
Salmeterol—Dizziness—Irinotecan—lung cancer	0.000128	0.000586	CcSEcCtD
Salmeterol—Urticaria—Etoposide—lung cancer	0.000128	0.000586	CcSEcCtD
Salmeterol—Abdominal pain—Etoposide—lung cancer	0.000128	0.000583	CcSEcCtD
Salmeterol—Body temperature increased—Etoposide—lung cancer	0.000128	0.000583	CcSEcCtD
Salmeterol—Urinary tract infection—Doxorubicin—lung cancer	0.000128	0.000583	CcSEcCtD
Salmeterol—Conjunctivitis—Doxorubicin—lung cancer	0.000128	0.000583	CcSEcCtD
Salmeterol—Asthenia—Cisplatin—lung cancer	0.000126	0.000578	CcSEcCtD
Salmeterol—Cardiac disorder—Methotrexate—lung cancer	0.000126	0.000577	CcSEcCtD
Salmeterol—Urticaria—Paclitaxel—lung cancer	0.000126	0.000574	CcSEcCtD
Salmeterol—Body temperature increased—Paclitaxel—lung cancer	0.000125	0.000572	CcSEcCtD
Salmeterol—Abdominal pain—Paclitaxel—lung cancer	0.000125	0.000572	CcSEcCtD
Salmeterol—Epistaxis—Doxorubicin—lung cancer	0.000124	0.000566	CcSEcCtD
Salmeterol—Vomiting—Irinotecan—lung cancer	0.000123	0.000564	CcSEcCtD
Salmeterol—Sinusitis—Doxorubicin—lung cancer	0.000123	0.000563	CcSEcCtD
Salmeterol—Immune system disorder—Methotrexate—lung cancer	0.000123	0.000562	CcSEcCtD
Salmeterol—Mediastinal disorder—Methotrexate—lung cancer	0.000123	0.00056	CcSEcCtD
Salmeterol—Rash—Irinotecan—lung cancer	0.000122	0.000559	CcSEcCtD
Salmeterol—Dermatitis—Irinotecan—lung cancer	0.000122	0.000558	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000122	0.000558	CcSEcCtD
Salmeterol—Headache—Irinotecan—lung cancer	0.000122	0.000555	CcSEcCtD
Salmeterol—Insomnia—Docetaxel—lung cancer	0.000121	0.000554	CcSEcCtD
Salmeterol—Diarrhoea—Cisplatin—lung cancer	0.000121	0.000551	CcSEcCtD
Salmeterol—Paraesthesia—Docetaxel—lung cancer	0.00012	0.00055	CcSEcCtD
Salmeterol—Vomiting—Gemcitabine—lung cancer	0.00012	0.000549	CcSEcCtD
Salmeterol—Dyspnoea—Docetaxel—lung cancer	0.00012	0.000546	CcSEcCtD
Salmeterol—Mental disorder—Methotrexate—lung cancer	0.000119	0.000545	CcSEcCtD
Salmeterol—Rash—Gemcitabine—lung cancer	0.000119	0.000545	CcSEcCtD
Salmeterol—Dermatitis—Gemcitabine—lung cancer	0.000119	0.000544	CcSEcCtD
Salmeterol—Hypersensitivity—Etoposide—lung cancer	0.000119	0.000543	CcSEcCtD
Salmeterol—Malnutrition—Methotrexate—lung cancer	0.000118	0.000541	CcSEcCtD
Salmeterol—Headache—Gemcitabine—lung cancer	0.000118	0.000541	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—lung cancer	0.000118	0.00054	CcSEcCtD
Salmeterol—Dyspepsia—Docetaxel—lung cancer	0.000118	0.000539	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—lung cancer	0.000117	0.000534	CcSEcCtD
Salmeterol—Hypersensitivity—Paclitaxel—lung cancer	0.000117	0.000533	CcSEcCtD
Salmeterol—Asthenia—Etoposide—lung cancer	0.000116	0.000529	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—lung cancer	0.000116	0.000529	CcSEcCtD
Salmeterol—Fatigue—Docetaxel—lung cancer	0.000116	0.000528	CcSEcCtD
Salmeterol—Nausea—Irinotecan—lung cancer	0.000115	0.000527	CcSEcCtD
Salmeterol—Constipation—Docetaxel—lung cancer	0.000115	0.000524	CcSEcCtD
Salmeterol—Pain—Docetaxel—lung cancer	0.000115	0.000524	CcSEcCtD
Salmeterol—Back pain—Methotrexate—lung cancer	0.000115	0.000524	CcSEcCtD
Salmeterol—Asthenia—Paclitaxel—lung cancer	0.000114	0.000519	CcSEcCtD
Salmeterol—Nausea—Gemcitabine—lung cancer	0.000112	0.000513	CcSEcCtD
Salmeterol—Vomiting—Cisplatin—lung cancer	0.000112	0.000512	CcSEcCtD
Salmeterol—Rash—Cisplatin—lung cancer	0.000111	0.000508	CcSEcCtD
Salmeterol—Dermatitis—Cisplatin—lung cancer	0.000111	0.000507	CcSEcCtD
Salmeterol—Feeling abnormal—Docetaxel—lung cancer	0.000111	0.000505	CcSEcCtD
Salmeterol—Diarrhoea—Etoposide—lung cancer	0.00011	0.000505	CcSEcCtD
Salmeterol—Ill-defined disorder—Methotrexate—lung cancer	0.00011	0.000502	CcSEcCtD
Salmeterol—Gastrointestinal pain—Docetaxel—lung cancer	0.00011	0.000501	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—lung cancer	0.000109	0.0005	CcSEcCtD
Salmeterol—Diarrhoea—Paclitaxel—lung cancer	0.000108	0.000495	CcSEcCtD
Salmeterol—Malaise—Methotrexate—lung cancer	0.000107	0.000488	CcSEcCtD
Salmeterol—Dizziness—Etoposide—lung cancer	0.000107	0.000488	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—lung cancer	0.000106	0.000486	CcSEcCtD
Salmeterol—Mediastinal disorder—Doxorubicin—lung cancer	0.000106	0.000485	CcSEcCtD
Salmeterol—Abdominal pain—Docetaxel—lung cancer	0.000106	0.000484	CcSEcCtD
Salmeterol—Body temperature increased—Docetaxel—lung cancer	0.000106	0.000484	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—lung cancer	0.000105	0.000481	CcSEcCtD
Salmeterol—Dizziness—Paclitaxel—lung cancer	0.000105	0.000478	CcSEcCtD
Salmeterol—Nausea—Cisplatin—lung cancer	0.000105	0.000478	CcSEcCtD
Salmeterol—Cough—Methotrexate—lung cancer	0.000103	0.000472	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—lung cancer	0.000103	0.000472	CcSEcCtD
Salmeterol—Vomiting—Etoposide—lung cancer	0.000103	0.000469	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—lung cancer	0.000103	0.000469	CcSEcCtD
Salmeterol—Rash—Etoposide—lung cancer	0.000102	0.000465	CcSEcCtD
Salmeterol—Dermatitis—Etoposide—lung cancer	0.000102	0.000465	CcSEcCtD
Salmeterol—Headache—Etoposide—lung cancer	0.000101	0.000462	CcSEcCtD
Salmeterol—Chest pain—Methotrexate—lung cancer	0.000101	0.000461	CcSEcCtD
Salmeterol—Arthralgia—Methotrexate—lung cancer	0.000101	0.000461	CcSEcCtD
Salmeterol—Myalgia—Methotrexate—lung cancer	0.000101	0.000461	CcSEcCtD
Salmeterol—Tension—Doxorubicin—lung cancer	0.000101	0.00046	CcSEcCtD
Salmeterol—Vomiting—Paclitaxel—lung cancer	0.000101	0.00046	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.0001	0.000458	CcSEcCtD
Salmeterol—Rash—Paclitaxel—lung cancer	9.98e-05	0.000456	CcSEcCtD
Salmeterol—Dermatitis—Paclitaxel—lung cancer	9.97e-05	0.000455	CcSEcCtD
Salmeterol—Discomfort—Methotrexate—lung cancer	9.97e-05	0.000455	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—lung cancer	9.96e-05	0.000455	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—lung cancer	9.92e-05	0.000453	CcSEcCtD
Salmeterol—Headache—Paclitaxel—lung cancer	9.92e-05	0.000453	CcSEcCtD
Salmeterol—Hypersensitivity—Docetaxel—lung cancer	9.88e-05	0.000452	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—lung cancer	9.86e-05	0.000451	CcSEcCtD
Salmeterol—Anaphylactic shock—Methotrexate—lung cancer	9.67e-05	0.000442	CcSEcCtD
Salmeterol—Asthenia—Docetaxel—lung cancer	9.63e-05	0.00044	CcSEcCtD
Salmeterol—Infection—Methotrexate—lung cancer	9.61e-05	0.000439	CcSEcCtD
Salmeterol—Nausea—Etoposide—lung cancer	9.59e-05	0.000438	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—lung cancer	9.52e-05	0.000435	CcSEcCtD
Salmeterol—Nervous system disorder—Methotrexate—lung cancer	9.48e-05	0.000433	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—lung cancer	9.43e-05	0.000431	CcSEcCtD
Salmeterol—Nausea—Paclitaxel—lung cancer	9.4e-05	0.000429	CcSEcCtD
Salmeterol—Skin disorder—Methotrexate—lung cancer	9.39e-05	0.000429	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—lung cancer	9.25e-05	0.000423	CcSEcCtD
Salmeterol—Diarrhoea—Docetaxel—lung cancer	9.18e-05	0.000419	CcSEcCtD
Salmeterol—Palpitations—Doxorubicin—lung cancer	9.07e-05	0.000414	CcSEcCtD
Salmeterol—Cough—Doxorubicin—lung cancer	8.95e-05	0.000409	CcSEcCtD
Salmeterol—Dizziness—Docetaxel—lung cancer	8.87e-05	0.000405	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—lung cancer	8.86e-05	0.000405	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Methotrexate—lung cancer	8.81e-05	0.000402	CcSEcCtD
Salmeterol—Insomnia—Methotrexate—lung cancer	8.75e-05	0.0004	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—lung cancer	8.73e-05	0.000399	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—lung cancer	8.73e-05	0.000399	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—lung cancer	8.73e-05	0.000399	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—lung cancer	8.7e-05	0.000398	CcSEcCtD
Salmeterol—Paraesthesia—Methotrexate—lung cancer	8.68e-05	0.000397	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.67e-05	0.000396	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—lung cancer	8.63e-05	0.000394	CcSEcCtD
Salmeterol—Dyspnoea—Methotrexate—lung cancer	8.62e-05	0.000394	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—lung cancer	8.54e-05	0.00039	CcSEcCtD
Salmeterol—Vomiting—Docetaxel—lung cancer	8.53e-05	0.00039	CcSEcCtD
Salmeterol—Dyspepsia—Methotrexate—lung cancer	8.51e-05	0.000389	CcSEcCtD
Salmeterol—Rash—Docetaxel—lung cancer	8.46e-05	0.000386	CcSEcCtD
Salmeterol—Dermatitis—Docetaxel—lung cancer	8.45e-05	0.000386	CcSEcCtD
Salmeterol—Headache—Docetaxel—lung cancer	8.4e-05	0.000384	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—lung cancer	8.37e-05	0.000382	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—lung cancer	8.37e-05	0.000382	CcSEcCtD
Salmeterol—Fatigue—Methotrexate—lung cancer	8.34e-05	0.000381	CcSEcCtD
Salmeterol—Infection—Doxorubicin—lung cancer	8.32e-05	0.00038	CcSEcCtD
Salmeterol—Pain—Methotrexate—lung cancer	8.27e-05	0.000378	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—lung cancer	8.21e-05	0.000375	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—lung cancer	8.17e-05	0.000373	CcSEcCtD
Salmeterol—Skin disorder—Doxorubicin—lung cancer	8.13e-05	0.000372	CcSEcCtD
Salmeterol—Nausea—Docetaxel—lung cancer	7.97e-05	0.000364	CcSEcCtD
Salmeterol—Feeling abnormal—Methotrexate—lung cancer	7.97e-05	0.000364	CcSEcCtD
Salmeterol—Gastrointestinal pain—Methotrexate—lung cancer	7.91e-05	0.000361	CcSEcCtD
Salmeterol—Urticaria—Methotrexate—lung cancer	7.68e-05	0.000351	CcSEcCtD
Salmeterol—Abdominal pain—Methotrexate—lung cancer	7.64e-05	0.000349	CcSEcCtD
Salmeterol—Body temperature increased—Methotrexate—lung cancer	7.64e-05	0.000349	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.63e-05	0.000348	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—lung cancer	7.57e-05	0.000346	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—lung cancer	7.52e-05	0.000343	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—lung cancer	7.47e-05	0.000341	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—lung cancer	7.37e-05	0.000337	CcSEcCtD
Salmeterol—Fatigue—Doxorubicin—lung cancer	7.22e-05	0.00033	CcSEcCtD
Salmeterol—Pain—Doxorubicin—lung cancer	7.16e-05	0.000327	CcSEcCtD
Salmeterol—Constipation—Doxorubicin—lung cancer	7.16e-05	0.000327	CcSEcCtD
Salmeterol—Hypersensitivity—Methotrexate—lung cancer	7.12e-05	0.000325	CcSEcCtD
Salmeterol—Asthenia—Methotrexate—lung cancer	6.94e-05	0.000317	CcSEcCtD
Salmeterol—Feeling abnormal—Doxorubicin—lung cancer	6.9e-05	0.000315	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—lung cancer	6.85e-05	0.000313	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—lung cancer	6.65e-05	0.000304	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—lung cancer	6.62e-05	0.000302	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—lung cancer	6.62e-05	0.000302	CcSEcCtD
Salmeterol—Diarrhoea—Methotrexate—lung cancer	6.62e-05	0.000302	CcSEcCtD
Salmeterol—Dizziness—Methotrexate—lung cancer	6.39e-05	0.000292	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—lung cancer	6.17e-05	0.000282	CcSEcCtD
Salmeterol—Vomiting—Methotrexate—lung cancer	6.15e-05	0.000281	CcSEcCtD
Salmeterol—Rash—Methotrexate—lung cancer	6.1e-05	0.000279	CcSEcCtD
Salmeterol—Dermatitis—Methotrexate—lung cancer	6.09e-05	0.000278	CcSEcCtD
Salmeterol—Headache—Methotrexate—lung cancer	6.06e-05	0.000277	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—lung cancer	6.01e-05	0.000274	CcSEcCtD
Salmeterol—Nausea—Methotrexate—lung cancer	5.74e-05	0.000262	CcSEcCtD
Salmeterol—Diarrhoea—Doxorubicin—lung cancer	5.73e-05	0.000262	CcSEcCtD
Salmeterol—Dizziness—Doxorubicin—lung cancer	5.54e-05	0.000253	CcSEcCtD
Salmeterol—Vomiting—Doxorubicin—lung cancer	5.32e-05	0.000243	CcSEcCtD
Salmeterol—Rash—Doxorubicin—lung cancer	5.28e-05	0.000241	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—lung cancer	5.27e-05	0.000241	CcSEcCtD
Salmeterol—Headache—Doxorubicin—lung cancer	5.25e-05	0.00024	CcSEcCtD
Salmeterol—Nausea—Doxorubicin—lung cancer	4.97e-05	0.000227	CcSEcCtD
Salmeterol—CYP3A5—Metabolism—ABCC3—lung cancer	2.39e-05	0.000337	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKR1C1—lung cancer	2.31e-05	0.000327	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADCY1—lung cancer	2.31e-05	0.000327	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—B4GALT5—lung cancer	2.28e-05	0.000323	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ATP5H—lung cancer	2.27e-05	0.000321	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—POMC—lung cancer	2.26e-05	0.00032	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PPP2R1B—lung cancer	2.25e-05	0.000318	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SMARCA4—lung cancer	2.25e-05	0.000318	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—UGT1A1—lung cancer	2.24e-05	0.000317	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTA4—lung cancer	2.22e-05	0.000314	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	2.17e-05	0.000307	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HSPB1—lung cancer	2.17e-05	0.000307	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTA2—lung cancer	2.17e-05	0.000306	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GNG11—lung cancer	2.16e-05	0.000306	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2E1—lung cancer	2.15e-05	0.000304	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTHLH—lung cancer	2.15e-05	0.000304	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NQO1—lung cancer	2.13e-05	0.000301	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTA1—lung cancer	2.09e-05	0.000296	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCC3—lung cancer	2.07e-05	0.000292	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALDOA—lung cancer	2.06e-05	0.000291	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLBD1—lung cancer	2.02e-05	0.000286	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ANXA1—lung cancer	2.02e-05	0.000285	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKR1C1—lung cancer	2e-05	0.000283	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOA3—lung cancer	2e-05	0.000283	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FLT1—lung cancer	1.95e-05	0.000276	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADCY1—lung cancer	1.94e-05	0.000275	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCG2—lung cancer	1.94e-05	0.000275	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—UGT1A1—lung cancer	1.94e-05	0.000275	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CG—lung cancer	1.94e-05	0.000274	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—STK11—lung cancer	1.92e-05	0.000271	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH3—lung cancer	1.91e-05	0.000271	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APP—lung cancer	1.91e-05	0.000271	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO2—lung cancer	1.91e-05	0.00027	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HPGDS—lung cancer	1.91e-05	0.00027	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF9—lung cancer	1.9e-05	0.000268	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPP2R1B—lung cancer	1.9e-05	0.000268	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GNG11—lung cancer	1.87e-05	0.000265	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.86e-05	0.000264	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD17B10—lung cancer	1.85e-05	0.000262	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—lung cancer	1.85e-05	0.000262	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—POMC—lung cancer	1.84e-05	0.000261	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2A6—lung cancer	1.83e-05	0.000259	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GCLC—lung cancer	1.83e-05	0.000259	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUNB—lung cancer	1.81e-05	0.000256	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALDOA—lung cancer	1.78e-05	0.000252	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTP1—lung cancer	1.77e-05	0.000251	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CG—lung cancer	1.76e-05	0.000249	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO1—lung cancer	1.73e-05	0.000245	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA3—lung cancer	1.73e-05	0.000245	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAT—lung cancer	1.73e-05	0.000244	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CKB—lung cancer	1.72e-05	0.000243	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CD—lung cancer	1.7e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.7e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADCY1—lung cancer	1.68e-05	0.000238	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCG2—lung cancer	1.68e-05	0.000238	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCB1—lung cancer	1.68e-05	0.000238	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—POMC—lung cancer	1.67e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HPGDS—lung cancer	1.65e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO2—lung cancer	1.65e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TYMS—lung cancer	1.65e-05	0.000233	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STK11—lung cancer	1.65e-05	0.000233	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPP2R1B—lung cancer	1.64e-05	0.000232	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6R—lung cancer	1.63e-05	0.000231	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—lung cancer	1.63e-05	0.000231	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.62e-05	0.000229	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CNDP2—lung cancer	1.62e-05	0.000229	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM2—lung cancer	1.62e-05	0.000229	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—lung cancer	1.6e-05	0.000227	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FOXO3—lung cancer	1.59e-05	0.000225	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GCLC—lung cancer	1.58e-05	0.000224	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2A6—lung cancer	1.58e-05	0.000224	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.58e-05	0.000223	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTMR3—lung cancer	1.57e-05	0.000223	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAP2K1—lung cancer	1.56e-05	0.00022	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2E1—lung cancer	1.55e-05	0.00022	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CD—lung cancer	1.55e-05	0.000219	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A1—lung cancer	1.55e-05	0.000219	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NQO1—lung cancer	1.54e-05	0.000217	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PGAM1—lung cancer	1.53e-05	0.000217	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ERCC2—lung cancer	1.53e-05	0.000217	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO1—lung cancer	1.5e-05	0.000212	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.5e-05	0.000212	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AVP—lung cancer	1.49e-05	0.00021	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CB—lung cancer	1.48e-05	0.00021	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.48e-05	0.000209	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2A7—lung cancer	1.46e-05	0.000207	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1R—lung cancer	1.43e-05	0.000203	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SDC4—lung cancer	1.43e-05	0.000203	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—lung cancer	1.43e-05	0.000202	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—lung cancer	1.41e-05	0.000199	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—STK11—lung cancer	1.39e-05	0.000196	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—RAF1—lung cancer	1.38e-05	0.000195	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—lung cancer	1.36e-05	0.000193	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CB—lung cancer	1.35e-05	0.000191	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2E1—lung cancer	1.35e-05	0.00019	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NQO1—lung cancer	1.33e-05	0.000188	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOA1—lung cancer	1.33e-05	0.000188	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RRM1—lung cancer	1.3e-05	0.000185	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA3—lung cancer	1.3e-05	0.000185	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.3e-05	0.000184	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—lung cancer	1.29e-05	0.000183	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.29e-05	0.000183	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB3—lung cancer	1.29e-05	0.000182	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—lung cancer	1.28e-05	0.000181	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAT—lung cancer	1.25e-05	0.000176	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—lung cancer	1.24e-05	0.000175	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—lung cancer	1.23e-05	0.000174	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—B4GALT5—lung cancer	1.23e-05	0.000173	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCB1—lung cancer	1.21e-05	0.000172	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—lung cancer	1.21e-05	0.000171	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—STK11—lung cancer	1.2e-05	0.00017	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR1—lung cancer	1.2e-05	0.000169	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA4—lung cancer	1.19e-05	0.000169	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMS—lung cancer	1.19e-05	0.000169	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—lung cancer	1.18e-05	0.000167	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—lung cancer	1.18e-05	0.000167	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA2—lung cancer	1.16e-05	0.000164	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—POMC—lung cancer	1.15e-05	0.000163	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOA1—lung cancer	1.14e-05	0.000161	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—lung cancer	1.13e-05	0.00016	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.13e-05	0.000159	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CREBBP—lung cancer	1.12e-05	0.000159	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA1—lung cancer	1.12e-05	0.000159	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A1—lung cancer	1.12e-05	0.000158	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—lung cancer	1.11e-05	0.000157	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCC3—lung cancer	1.11e-05	0.000157	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ERCC2—lung cancer	1.11e-05	0.000157	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAT—lung cancer	1.08e-05	0.000153	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.07e-05	0.000152	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKR1C1—lung cancer	1.07e-05	0.000152	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CD—lung cancer	1.06e-05	0.000151	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCB1—lung cancer	1.05e-05	0.000149	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—lung cancer	1.05e-05	0.000149	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UGT1A1—lung cancer	1.04e-05	0.000148	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APC—lung cancer	1.04e-05	0.000147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—lung cancer	1.04e-05	0.000147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KIT—lung cancer	1.04e-05	0.000147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—NRAS—lung cancer	1.04e-05	0.000147	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMS—lung cancer	1.03e-05	0.000146	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGF—lung cancer	1.03e-05	0.000145	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—lung cancer	1.02e-05	0.000144	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GNG11—lung cancer	1.01e-05	0.000142	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAPK3—lung cancer	9.95e-06	0.000141	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—POMC—lung cancer	9.89e-06	0.00014	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BRAF—lung cancer	9.76e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A1—lung cancer	9.67e-06	0.000137	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6R—lung cancer	9.64e-06	0.000136	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREBBP—lung cancer	9.63e-06	0.000136	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ERCC2—lung cancer	9.59e-06	0.000136	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA1—lung cancer	9.58e-06	0.000136	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDOA—lung cancer	9.57e-06	0.000135	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—lung cancer	9.46e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA3—lung cancer	9.29e-06	0.000131	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CB—lung cancer	9.27e-06	0.000131	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAP2K1—lung cancer	9.19e-06	0.00013	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—lung cancer	9.19e-06	0.00013	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CD—lung cancer	9.13e-06	0.000129	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	9.04e-06	0.000128	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG2—lung cancer	9.04e-06	0.000128	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADCY1—lung cancer	9.04e-06	0.000128	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—lung cancer	8.94e-06	0.000126	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HPGDS—lung cancer	8.87e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO2—lung cancer	8.87e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPP2R1B—lung cancer	8.81e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—lung cancer	8.75e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—lung cancer	8.6e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCLC—lung cancer	8.5e-06	0.00012	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2A6—lung cancer	8.5e-06	0.00012	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—POMC—lung cancer	8.33e-06	0.000118	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA1—lung cancer	8.3e-06	0.000117	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	8.21e-06	0.000116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDM2—lung cancer	8.18e-06	0.000116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RAF1—lung cancer	8.15e-06	0.000115	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CREBBP—lung cancer	8.11e-06	0.000115	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—lung cancer	8.06e-06	0.000114	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO1—lung cancer	8.06e-06	0.000114	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—lung cancer	8.01e-06	0.000113	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MTOR—lung cancer	7.96e-06	0.000113	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CB—lung cancer	7.96e-06	0.000113	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	7.95e-06	0.000112	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CD—lung cancer	7.69e-06	0.000109	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—lung cancer	7.65e-06	0.000108	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—lung cancer	7.64e-06	0.000108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HRAS—lung cancer	7.6e-06	0.000107	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—lung cancer	7.59e-06	0.000107	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—lung cancer	7.58e-06	0.000107	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—lung cancer	7.39e-06	0.000105	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—lung cancer	7.32e-06	0.000104	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—lung cancer	7.31e-06	0.000103	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—lung cancer	7.27e-06	0.000103	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2E1—lung cancer	7.23e-06	0.000102	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—POMC—lung cancer	7.21e-06	0.000102	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NQO1—lung cancer	7.15e-06	0.000101	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—lung cancer	7.13e-06	0.000101	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUN—lung cancer	7.11e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CREBBP—lung cancer	7.03e-06	9.94e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—lung cancer	6.92e-06	9.79e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—lung cancer	6.89e-06	9.75e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—lung cancer	6.88e-06	9.73e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—lung cancer	6.71e-06	9.49e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CB—lung cancer	6.7e-06	9.48e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CD—lung cancer	6.66e-06	9.42e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—lung cancer	6.64e-06	9.4e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—lung cancer	6.58e-06	9.3e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—lung cancer	6.56e-06	9.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—STK11—lung cancer	6.44e-06	9.11e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—lung cancer	6.38e-06	9.02e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—lung cancer	6.21e-06	8.79e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—lung cancer	6.15e-06	8.7e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NRAS—lung cancer	6.14e-06	8.68e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—lung cancer	5.96e-06	8.43e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK3—lung cancer	5.88e-06	8.31e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CB—lung cancer	5.81e-06	8.21e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAT—lung cancer	5.8e-06	8.21e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—lung cancer	5.79e-06	8.19e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—lung cancer	5.75e-06	8.14e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—lung cancer	5.72e-06	8.09e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—lung cancer	5.65e-06	8e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCB1—lung cancer	5.64e-06	7.98e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—lung cancer	5.59e-06	7.91e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMS—lung cancer	5.54e-06	7.84e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—lung cancer	5.52e-06	7.81e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—lung cancer	5.48e-06	7.75e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—lung cancer	5.28e-06	7.47e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A1—lung cancer	5.19e-06	7.35e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ERCC2—lung cancer	5.15e-06	7.29e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—lung cancer	5.02e-06	7.1e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—lung cancer	4.85e-06	6.86e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—lung cancer	4.78e-06	6.77e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—lung cancer	4.69e-06	6.64e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—lung cancer	4.62e-06	6.53e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRAS—lung cancer	4.49e-06	6.35e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA1—lung cancer	4.45e-06	6.3e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—lung cancer	4.3e-06	6.08e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—lung cancer	4.09e-06	5.78e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—lung cancer	4.07e-06	5.75e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—lung cancer	3.96e-06	5.61e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—POMC—lung cancer	3.87e-06	5.48e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CREBBP—lung cancer	3.77e-06	5.33e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CD—lung cancer	3.58e-06	5.06e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—lung cancer	3.54e-06	5.01e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—lung cancer	3.53e-06	4.99e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—lung cancer	3.34e-06	4.72e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CB—lung cancer	3.12e-06	4.41e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—lung cancer	3.09e-06	4.37e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—lung cancer	2.89e-06	4.09e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—lung cancer	2.69e-06	3.81e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—lung cancer	2.57e-06	3.63e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—lung cancer	1.9e-06	2.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—lung cancer	1.55e-06	2.2e-05	CbGpPWpGaD
